“Ozempic (semaglutide injection) is not licenced for the treatment of weight loss. No evidence of hair loss exists for Ozempic in the clinical trials for Type-2 diabetes.

“In clinical trials for Wegovy(semaglutide injection) hair loss was noticed and is included in the SmPC as a side effect. Most of the events of hair loss in Wegovy-treated adult patients were resolved or were resolving on continued treatment.

“Hair loss was reported in 3 percent of Wegovy-treated adult patients vs 1 percent of placebo-treated adult patients. None of the events of alopecia were serious, and most of the events were mild in severity.

“More than half of the events of alopecia were assessed by the investigator as unlikely to be related to trial products.”

And a rep for Eli Lilly said: “Patient safety is Lilly’s top priority. We take any reports regarding patient safety extremely seriously and actively monitor, evaluate, and report safety information for all our medicines.

“The Mounjaro (tirzepatide) Patient Information Leaflet warns that hair loss is a common side effect in patients treated with Mounjaro for weight management.

“We encourage patients to consult their doctor or other healthcare professional regarding any side effects they may be experiencing and to ensure that they are getting genuine Lilly medicine.”